



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	125810	"TBSF" High Purity Factor IX Concentrate
ARTG entry for	Medicine Listed (Export Only)	
Sponsor	CSL Behring Australia Pty Ltd	
Postal Address	189-209 Camp Road, BROADMEADOWS, VIC, 3047 Australia	
ARTG Start Date	1/03/2006	
Product Category	Medicine	
Status	Active	
Approval Area	Export only Medicines	

Conditions

Except where the sponsor has been contracted by an overseas party to manufacturer the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods, and upon the request of the Head, Office of Prescription Medicines Authorisation Branch, Therapeutic Goods Administration, shall produce such evidence to this officer.

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

The therapeutic goods grouped in this registration/listing as export only goods under the following names are included in the Australian Register of Therapeutic Goods and may not be supplied in Australia. Export Name(s) to be added:

The sponsor shall hold stability data to support the claimed shelf life of the listed medicine according to the labelled storage conditions except where: (i) each overseas importer accepts responsibility for holding stability data for this product; (ii) the sponsor has a written agreement to this effect from each overseas importer; and (iii) the sponsor retains copies of all such agreements while the medicine remains listed on the ARTG.

This product must not be supplied for sale in Australia, including supply via duty free outlets.

Products

1 . "TBSF" High Purity Factor IX Concentrate

Product Type	Composite Pack	Effective Date	1/03/2006
---------------------	----------------	-----------------------	-----------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

"TBSF" High Purity Factor IX Concentrate is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia B. "TBSF" High Purity Factor IX Concentrate is not indicated for the treatment of factor II, VII or X deficiencies because it does not contain therapeutic levels of these coagulation factors. "TBSF" High Purity Factor IX Concentrate is not indicated for the treatment of haemophilia A patients with factor VIII inhibitors.

Warnings

No Warnings included on Record

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Vial	Not recorded	2 Years	Store at 2 to 8 degrees Celsius	Not recorded	Do not Freeze Refrigerate Protect from Light

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Pack Size/Poison information

Pack Size
500 IU

Poison Schedule
Not scheduled. Not considered by committee

Components

1 . "TBSF" High Purity Factor IX Concentrate

Dosage Form Injection, powder for
Route of Administration Intravenous
Visual Identification A white freeze dried powder plug or friable solid

Active Ingredients

Factor IX 50 IU/mL

Other Ingredients (Excipients)

Antithrombin III
chloride
citrate
heparin sodium
phosphate
Plasma proteins
sodium

2 . Water for Injections - Diluent

Dosage Form Injection, diluent for
Route of Administration Intravenous
Visual Identification Clear, colourless solution free from visible particles

Other Ingredients (Excipients)

water for injections

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary